These medications are inhaled through your mouth so they can directly reach your lungs. If your healthcare provider ...

If an inhaled steroid does not help or does not relieve your symptoms enough, current guidelines from the National Heart, Lung, and Blood Institute recommend adding a long-acting bronchodilator ...

a questionnaire was administered that included questions about smoking and inhaler use. SI subjects also received a MDI containing either placebo or an anticholinergic bronchodilator (ipratropium ...

First: use your inhaled bronchodilator. If symptoms stop completely: repeat inhaled bronchodilator when necessary; consider a short course of oral corticosteroid after third dose for acute ...

Amid mixed evidence, the use of inhaled antibiotics for bronchiectasis has been considered controversial, but the approach has nonetheless received conditional endorsement in ERS guidelines from ...

Improper Inhaler Use by People With COPD Is Common, Worsening Disease By Ernie Mundell HealthDay Reporter FRIDAY, Aug. 23, 2024 (HealthDay News) -- Millions of people rely on medicines delivered ...

You should stop taking any long-acting inhalers which contain inhaled corticosteroids or bronchodilators. However, you can continue to use a quick-acting inhaler (such as VENTOLIN) during an acute ...

In the D-A-CH region, the projected revenue in the Bronchodilator Drugs market is expected to reach US$1.44bn by 2024. It is anticipated that the revenue will exhibit an annual growth rate (CAGR ...

GOLD COPD Report includes updated research and recommendations that reflect shifts in thinking on COPD management.

The phase IIIA trials randomized 792 patients ages 12 and older with severe asthma in a 2:1 ratio to depemokimab (100 mg ...

The Bronchodilator Drugs market in Hong Kong is forecasted to achieve a revenue of US$57.46m in 2024. This market is expected to experience a steady growth rate of 3.86% annually from 2024 to 2029 ...

Marlboro cigarette maker Philip Morris has been forced to sell a British maker of asthma inhalers at a steep loss after a growing backlash from health groups opposed to its ownership.